ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.
Yaru XuZhaoning WangMartin SjöströmSu DengChoushi WangNickolas A JohnsonJulisa GonzalezXiaoling LiLauren A MetangCarla Rodriguez TiradoAtreyi MukherjiGarrett WainwrightXinzhe YuYuqiu YangSpencer BarnesMia HofstadHong ZhuAriella HankerHousheng Hansen HeJuliet ChenZhao WangGanesh RajCarlos ArteagaFelix FengYunguan WangTao WangPing MuPublished in: bioRxiv : the preprint server for biology (2023)
This study reveals a novel epigenetic mechanism regulating tumor lineage plasticity and therapy response, enhances understanding of drug resistance and unveils a new therapeutic strategy for prostate cancer and other malignancies. Our findings also illuminate TET2's oncogenic role and mechanistically connect TET2-driven epigenetic rewiring to lineage plasticity and therapy resistance.